EGFR and non-small cell lung carcinoma: The clinical significance of the current findings should be viewed in the context in China, where less than 20% of NSCLC patients are tested for EGFR mutations while in other Asian countries, 30%-80% of NSCLC patients are tested for EGFR mutations31.